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Introduction: Care bundles help healthcare professionals provide the best care possible 
in a structured and reliable way. The purpose of this study was to develop and apply 
an instrument for inpatient follow-up by clinical pharmacists, and evaluate its results.
Methods: The care bundle was based on previously validated instruments. Population 
consisted of patients monitored by clinical pharmacists at a general hospital. The study 
was conducted in two phases: the first involved the development and implementation 
of the bundle, and the evaluation of pharmaceutical interventions; the second involved 
analyzing data from patients treated with the bundle over one year.
Results: The bundle included fourteen pharmaceutical follow-up criteria used in 
different patterns by each area of care. In the first phase of the study, 3263 patients 
were monitored and 536 pharmaceutical interventions were performed, with an 85.3% 
compliance rate. In the second phase of the study, follow-up data was collected from 
21,214 patients. The bundle criteria were used in a similar way in clinical, surgical 
and cancer patients. Pharmacotherapy review was the most prevalent intervention 
in all cases (60.1%). Hospital discharge planning and medication reconciliation were 
performed with a similar frequency in clinical, surgical, pediatric and general patients.
Conclusions: The development and validation of a bundle aimed at guiding the 
clinical activities of pharmacists helped standardize procedures and interventions. 
Pharmacotherapy review was the bundle criterion with the highest rate of application 
and interventions due to the hospital’s complexity and the need to consider individual 
patient needs and follow institutional policies.
Keywords: Pharmacy service, hospital; clinical pharmacy; pharmaceutical intervention; 
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INTRODUCTION
In hospital settings, ‘clinical pharmacy’ refers to the contribution of hospital 
pharmacists to drug therapy as part of the comprehensive care offered to patients 
in collaboration with physicians and nursing staff. The goal of clinical pharmacy 
services is to optimize the efficiency, effectiveness and safety of pharmacotherapy. 
Recent studies concluded that clinical pharmacy interventions contribute to 
the improvement of patient outcomes1-3. Pharmacist participation in medical 
rounds, medication reconciliation at admission or discharge, and the provision 
of specific pharmaceutical services reduces the frequency of adverse drug 
events and medication errors, improving both treatment adherence and patients’ 
medication knowledge1. Clinical pharmacy services are also associated with cost 
savings1-3. A number of studies have demonstrated the clinical and economic 
benefits of clinical pharmacy interventions in hospital and primary care settings1-3. 
A Pharmaceutical Risk Score was also developed to assess pharmacological risk 
factors in hospitalized patients and contribute to pharmaceutical monitoring4. The 
scores can be used to classify patients into risk groups (high, moderate or low) 
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and help hospital pharmacists direct their efforts more 
effectively4. Once priorities for pharmaceutical monitoring 
have been identified, the follow-up procedures can 
be determined. The complexity of new drug therapies 
and improvement of therapeutic regimens due to the 
results of pharmaceutical interventions reinforce the 
importance of quality pharmaceutical care. The Institute 
of Healthcare Improvement developed the concept of 
‘bundle’ to help healthcare professionals provide the 
best and most reliable care possible to patients receiving 
specific treatments with inherent risks5.
A bundle is a structured way of improving patient 
care processes through a set of evidence-based 
practices that, when performed collectively and reliably, 
improve patient outcomes5. Effective follow-up requires 
the establishment of standardized pharmaceutical 
criteria adjusted to patient characteristics. To this 
end, checklists offer a moderate level of guidance but 
are still flexible enough to allow healthcare workers 
to use their own judgment6.
Systematic reviews and meta-analyses have assessed 
the effectiveness of bundles in several areas of health 
care, including the prevention of catheter infections in 
neonatology and adverse events in pediatric patients7-9. 
Most meta-analyses include before-and-after studies 
whose results demonstrate a reduction in health care 
risks with the use of bundles relative to usual care9.
FASTHUG is a mnemonic designed to systematize 
the care of critical patients, and is used by intensive care 
practitioners around the world. It lists seven items that 
must be reviewed daily to standardize care and prevent 
omissions in intensive care10. Notably, the FASTHUG 
mnemonic was not designed to identify problems 
related to the drugs commonly used in ICU settings10. 
Therefore, a modified mnemonic, FASTHUG-MAIDENS, 
was developed by clinical pharmacists to ensure that 
the essential standards of pharmaceutical care would 
be consistently met in professional practice11.
The purpose of developing a new bundle focused 
on pharmacotherapy is to provide a more flexible 
instrument that is applicable to different settings, from 
pediatric to adult patients in both critical and general 
care, while also contemplating institutional protocols 
and allowing for the monitoring of patients with 
expected discharge dates. Such an instrument could 
also be useful for training and guiding pharmaceutical 
follow-up in multi-professional teams.
The objective of this study was to describe the 
development of a care bundle for inpatient follow-up 
by clinical pharmacists, and evaluate the results of 
this protocol in a general hospital.
METHODS
The study was conducted at the Hospital de 
Clínicas de Porto Alegre (HCPA), a tertiary university 
hospital accredited by the Joint Commission 
International. The HCPA has approximately 
850 beds and 19 clinical pharmacists, who work in 
the following areas: clinical care (general practice, 
clinical specialties and psychiatry); surgery (general 
surgery, specialties and solid organ transplants); 
oncology (adult oncohematological patients, pediatric 
and hematopoietic stem cell transplantation, pediatric 
cancer); maternal and child care (maternity and 
neonatology); and critical care (emergency and 
pediatric/adult intensive care units). Follow-up in 
these areas is conducted according to patient needs 
and pre-established criteria for each particular sector.
Development of the pharmaceutical care bundle
The bundle was developed based on validated 
instruments used at the HCPA, including FASTHUG10 
and FASTHUG-MAIDENS11, which include items 
that should be reviewed on a daily basis to ensure 
standardized care and avoid any omissions, thereby 
meeting the essential goals of pharmaceutical 
care12,13. Examples of items in these protocols include 
feeding, analgesia, sedation, institutional protocols, 
and medication reconciliation.
Population, data collection and outcome  
measurement
The study population consisted of patients 
managed by pharmacists from the clinical, surgical, 
oncological, pediatric, maternal and critical care units. 
The study was conducted in two phases. The first 
was a three-month pilot project (May to July 2017) to 
validate the pharmaceutical care bundle. The bundle 
was evaluated by correlating each item with the 
pharmaceutical interventions performed in the same 
period. The results of the pharmaceutical interventions 
were assessed based on medical compliance rates.
The pilot project allowed for adjustments to be 
made to the instrument prior to the next phase of the 
study, which consisted of monitoring patients treated 
with the pharmaceutical care bundle for a one-year 
period (January to December 2018). Information 
on the patients monitored by clinical pharmacists, 
as well as the bundle items used in each case, were 
recorded in a productivity monitoring system consisting 
of a Microsoft Excel (version 2010) spreadsheet, 
for further data analysis.
Ethics approval
This study was conducted according to Brazilian 
National Health Council guidelines (Resolution 
466/12) and approved by the HCPA Research and 
Postgraduate Group.
RESULTS
Table 1 shows the pharmaceutical care bundle 
and adjustments made after the pilot phase.
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Table 1: Proposed pharmaceutical care bundle (Adapted from the FASTHUG-MAIDENS11).
Item Criteria Description
1 Pharmacotherapy review Evaluating the list of health problems and prescribing medications according 
to indications for use and effectiveness and safety parameters, including 
adverse reactions, drug interactions, therapeutic duplication, allergies and 
duration of therapy.
2 Medication reconciliation Performing medication reconciliation on admission, transferring between 
units/specialties or hospital discharge to identify and resolve discrepancies. 
3 Nutrition Identifying the nutrition administration route (enteral or parenteral)
Evaluating alternative dosage forms and suggesting changes in 
administration routes as needed.
Reviewing interaction/incompatibilities between drugs and nutrients.
4 Analgesia Reviewing the prescribed analgesics according to pain/analgesia protocols (pain 
characteristics, location and intensity; dose, interval and drug infusion time)
5 Sedation Reviewing prescribed sedatives according to sedation protocols (sedation 
rating scale where applicable, dose, interval, and drug infusion time).
Evaluating medications with a potential risk of falling and excessive sedation.
6 Anticoagulation/ risk of VTE Evaluating oral anticoagulant use (monitoring INR and relevant drug 
interactions) and PTE/DVT treatment with anticoagulant EV and SC 
(indication of use, dose, route of administration and monitoring aPTT and 
anti-Xa where applicable).
Assessing the risk of PTE/DVT according to thromboembolic event 
prevention protocol.
7 Delirium Evaluating drugs with the potential to induce or worsen delirium (hyperactive, 
hypoactive or mixed) and treatment according to protocols.
Checking the history of alcoholism or psychoactive substance use for risk of 
abstinence and treatment as indicated.
8 Physiological habits/stress 
ulcer prophylaxis
Checking physiological habits and considering medications that may change 
them (nausea, vomiting, constipation, diarrhea, urinary retention) and the 
need for pharmacological management.
Evaluating the need for stress ulcer prophylaxis, including doses, monitoring 
of complications and treatment time.
9 Vital signs Reviewing vital signs (blood glucose, blood pressure and heart rate, etc.), 
considering medications that could alter them and verifying the need for 
pharmacological management.
10 Antimicrobials Evaluating antimicrobial therapy (empirical, prophylactic or culture-guided 
treatment/sensitivity testing) based on guidelines.
Optimizing therapy (doses, treatment time and decolonization).
11 Dose adjustment Reviewing renal function, liver tests and other parameters that could alter 
patient dosage.
Therapeutic monitoring of medications
12 Laboratory results Checking laboratory tests and intervening as necessary, considering drug-
induced changes.
13 Hospital discharge Planning and orienting hospital discharge for priority care lines and/or 
according to patient requirements.
Evaluating access to the medications prescribed at discharge.
Providing safety information for medications dispensed for home use.
14 Validation of medications 
brought by the patient
Evaluating medications brought by the patient, register in the medical record 
to ensure traceability and safe use during hospitalization.
VTE: venous thromboembolism; PTE: Pulmonary thromboembolism; DVP: deep vein thrombosis; INR: international normalized ratio; 
aPTT: Activated partial thromboplastin time; EV: endovenous; SC: subcutaneous.
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The first phase of the study aimed to validate the 
pharmaceutical bundle. This stage involved 3,263 patients 
and 536 pharmaceutical interventions, which were 
then classified according to bundle item (Figure 1).
The mean number of interventions per patient 
was 0.16 in the first stage, and overall compliance 
with these interventions was 85.3%. Table 2 presents 
data on intervention adherence for each bundle 
item. The categories with the highest frequency 
of pharmaceutical interventions were medication 
review (53.4%) and reconciliation (16.8%); the rates 
of compliance with these interventions were 86.4% 
and 86.7%, respectively. Although other bundle items 
were associated with fewer interventions, they had 
higher adherence rates; this was the case for venous 
thromboembolism (VTE) risk (90.5%), delirium, hospital 
discharge and drug validation (100%) (Table 2).
In the second phase of the study, follow-up data 
were collected for 21,214 patients treated with the 
pharmaceutical bundle. Table 3 shows the results of 
pharmaceutical follow-up and bundle items applied 
in each area of care. Overall results for the second 
phase of the study revealed an adherence rate of 

































































































































Figure 1: Pharmaceutical interventions performed in the bundle validation phase (n = 536).
Table 2: Pharmaceutical interventions and adherence according to bundle categories in the first stage of the study (n = 536).
Bundle criteria
Pharmaceutical interventions Intervention adherence 
n (%) n (%)
Pharmacotherapy review 286 (53.4%) 247 (86.4%)
Medication reconciliation 90 (16.8%) 78 (86.7%)
Nutrition 40 (7.5%) 30 (75%)
Analgesia 36 (6.7%) 22 (61.1%)
Sedation 4 (0.7%) 3 (75%)
Anticoagulation/ VTE risk 21 (3.9%) 19 (90.5%)
Delirium 2 (0.4%) 2 (100%)
Continua...
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Bundle criteria
Pharmaceutical interventions Intervention adherence 
n (%) n (%)
Physiological habits 5 (0.9%) 4 (80%)
Vital signs 7 (1.3%) 6 (85.7%)
Antimicrobials 35 (6.5%) 29 (82.9%)
Dose Adjustment 35 (6.5%) 27 (77.1%)
Laboratory results 17 (3.2%) 16 (94.1%)
Hospital discharge 12 (2.2%) 12 (100%)
Validation of current patient 
medications at admission 5 (0.9%) 5 (100%)
VTE: venous thromboembolism





























191 (17.5%) 3.082 
(14.5%)
Admission 842 (14.7%) 533 (10.2%) 510 
(26.0%)
0 189 (8.2%) 0 2074 (9.8%)
Transference 39 (0.7%) 72 (1.4%) 139 (7.1%) 0 95 (4.1%) 0 345 (1.6%)
Hospital 
discharge
85 (1.5%) 151 (2.9%) 269 
(13.7%)





























87 (3.8%) 0 7.423 
(35.0%)







176 (9.0%) 2.398 
(49.1%)
6 (0.3%) 9 (0.8%) 6.557 
(30.9%)











33 (1.4%) 0 4.648 
(21.9%)







































572 (10.0%) 444 (8.5%) 362 
(18.4%)
103 (2.1%) 232 
(10.1%)
269 (24.6%) 1.982 (9.3%)
Continua...
Table 2: Continuação
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Anticoagulant 178 (3.1%) 129 (2.5%) 19 (1.0%) 3 (0.1%) 2 (0.1%) 5 (0.4%) 336 (1.6%)
Oral 
chemotherapy








136 (2.4%) 203 (3.9%) 303 
(15.4%)
8 (0.2%) 144 (6.3%) 209 (19.1%) 1003 (4.7%)
Drug 
dispensing
66 (1.1%) 68 (1.3%) 0 4 (0.1%) 40 (1.7%) 140 (12.8%) 318 (1. +5%)
Table 3: Continuação
DISCUSSION
In the first stage of the study, the instrument was 
developed and validated by analyzing interventions 
implemented with the pharmaceutical care bundle.
The item with the highest frequency of interventions 
was pharmacotherapy review, followed in descending 
order by medication reconciliation, nutrition, analgesia, 
antimicrobials and dose adjustment (Figure 1 and 
Table 2). Interventions in these categories may have 
been more frequent because they are associated with 
the initial review performed on hospitalization and to 
pharmaceutical monitoring, as well as the adjustment 
of prescription dosage according to institutional 
protocols (e.g. analgesia, antimicrobial policy, serum 
vancomycin levels, monitoring of oral anticoagulants), 
which can affect laboratory results and prompt the 
need for further pharmacological interventions.
Adherence rates and the mean number of 
interventions per patient were consistent with the 
results of previous studies14-16. Pharmaceutical 
interventions were fully implemented for the items 
delirium, hospital discharge and validation of medication 
use. The small number of interventions for the item 
“delirium” is justified by the fact that this symptom is 
more frequent in clinical wards, where health care 
workers are also better able to detect it. Interventions at 
hospital discharge, including medication reconciliation, 
aim to ensure appropriate pharmacotherapy and 
help patients access the health system by providing 
the appropriate prescriptions and documents. The 
validation of medications brought by the patient for 
use in the hospital provides an opportunity for a 
review of past prescriptions, and for an assessment 
of patients’ habits regarding the acquisition, use, and 
conservation of the medication, which could lead to 
interventions to promote safer medication use17,18.
A review of laboratory parameters showed that 
adherence to the interventions was high, likely due 
to their relevance to treatment efficacy and drug 
safety. These are often structured interventions 
that are already systematically implemented by the 
hospital pharmacy service. The adherence rates for 
other interventions remained above 60%, similar to 
previous studies16,19. It is important to note that many 
pharmaceutical interventions are educational in 
nature, which may have contributed to the variations 
in acceptability rates15.
The distribution of interventions related to each 
item was consistent with patient profiles. The most 
prevalent bundle category in all areas of care was 
medication review, which is performed using medical 
prescription data and patient records. Clinical 
pharmacists perform this assessment to prevent or 
resolve drug-related problems, which are the main 
cause of adverse events and could lead to outcomes 
such as increased length of stay, morbidity, mortality 
and greater hospital costs14.
Clinical, surgical and cancer patients had similar 
follow-up profiles. The most prevalent interventions in 
these departments were associated with institutional 
protocols (analgesia, venous thromboembolism 
prophylaxis and oral anticoagulation management); the 
next most frequent interventions were the assessment 
of vital signs, laboratory results, physiological functions 
and nutritional status. The analysis of these items 
contributes to the evaluation of the efficacy and 
safety of pharmacotherapy and could reveal the need 
for further pharmaceutical interventions. Examples 
include dose adjustment; discontinuing medication 
due to suspected adverse reactions identified in 
vital signs or altered laboratory tests; and assessing 
potential interactions between medications and 
enteral nutrition.
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Analgesia interventions were more prevalent in 
critical, clinical and cancer patients. Compliance with 
the pain management scale and appropriate use of 
analgesics are important strategies in these populations, 
and especially in cancer pain management. Pain is 
reported by 39.3 to 55% of cancer patients undergoing 
treatment and 66.4% of advanced cancer patients20,21.
The comparison of clinical and surgical patients 
revealed that the latter were less likely to require a 
medication review due to their high turnover rates. 
Pharmaceutical follow-up was more frequent in 
surgical patients, since pharmacists must review 
the laboratory results of transplant recipients to 
examine their immunosuppressant levels and make 
any necessary adjustments, as well as monitor and 
adjust the doses of any other prescriptions.
Patients admitted to adult or pediatric intensive care 
units and those seen in emergency services share 
a similar feature: an unstable clinical condition that 
may lead them to become chronically critically ill over 
time. The most prevalent interventions in critically ill 
patients were associated with organ dysfunction. Issues 
observed in this population included hemodynamic 
instability, ventilatory insufficiency, acute renal 
failure, poor perfusion, high risk of thrombosis due 
to prolonged bed rest, suspected sepsis or septic 
shock, and other complications that occur during 
hospitalization in clinical, surgical or specialized 
wards. Emergency services treat patients who meet 
criteria for stroke, acute coronary syndrome and 
infarction protocols. This underscores the need to 
systematically monitor laboratory tests at least once 
a day for severe cases in emergency wards and 
ICUs; to ensure patient comfort during mechanical 
ventilation; and provide adequate pain management. 
However, the frequency with which some items were 
used in emergency care as compared to ICU settings 
differed, probably because the oral route is available 
in most patients in emergency care, while most ICU 
patients receive full enteral nutrition10,11.
Although the profile of pediatric ICU patients 
is similar to that of adults, the need to monitor the 
risk of VTE is mostly associated with adult patients. 
The incidence of VTE in pediatric populations 
is not known. The first data on the subject were 
published in 1994 based on the Canadian Childhood 
Thrombophilia registry, which reported an incidence 
of 0.07 per 10 000 children from 1 month to 18 years 
old. In Europe, the estimated incidence is 0.07 to 0.14 
per 10 000 children, which is much lower than that 
observed in adults (5.6 to 16 per 10 000)22.
Antimicrobial monitoring in neonatology was very 
frequent, since the most common diseases in this 
population include those identified using a neonatal 
sepsis protocol (early or late onset), as well as 
STORCH infections (e.g. measles, toxoplasmosis, 
rubella, cytomegalovirus, herpes), and necrotizing 
enterocolitis. Thus, the monitoring of laboratory results 
was also common in this population, though not as 
frequent as the prescription of antimicrobials due to the 
impossibility of further follow-up. Antimicrobial monitoring 
in the pediatric patient group included interventions 
performed in general pediatric wards and the treatment 
of common childhood diseases, as well as the use of 
antimicrobials by patients with short bowel syndrome, 
cystic fibrosis and recent liver transplantation, since 
the HCPA is a reference hospital for these conditions. 
It is also important to note that the ‘nutrition’ bundle 
item in pediatric patients included the consideration of 
alternative pharmaceutical formulations, since liquid 
formulations are often unavailable for these patients17. 
Vital signs in the maternal and child care group were 
not monitored by pharmacists; neonatal patients and 
pregnant women are closely monitored by the medical 
and nursing teams according to pre-established 
protocols, allowing pharmacists to concentrate on 
other aspects of pharmacotherapy that receive less 
attention from the rest of the multidisciplinary team.
Hospital discharge planning and medication 
reconciliation were similarly frequent in clinical, 
surgical, pediatric and general patients since the 
procedures involved in reconciliation, planning and 
education at hospital discharge are the same in these 
departments. Some issues addressed by interventions 
in these populations were the use of anticoagulants, 
oral chemotherapy, polypharmacy and medication 
adherence difficulties. Pediatric discharge planning 
includes counseling patients with chronic polypharmacy 
about fractional dosing, and providing information on 
liver transplantation, fibrocystic drugs, and intestinal 
rehabilitation, as needed. During discharge from the 
maternal and child health department, pharmacists 
must also consider the guidelines for pregnant and 
puerperal women receiving antimicrobial treatments, 
prophylaxis for vertical transmission of HIV and 
issues related to the discharge of newborns who 
have been prescribed different types of medications, 
including anticonvulsants.
All departments had to discharge patients with 
complex needs, provide guidance about medication 
acquisition, and inform patients about administration 
tubes and pharmaceutical formulations adapted for 
home use.
Medication reconciliation upon hospital discharge 
was more frequent among surgical and cancer 
patients due to the orientations and educational 
materials given to transplant recipients (i.e., to help 
organize the medications they will be using at home). 
In neonatology, medication reconciliation is only 
necessary on hospital discharge, while in pediatric 
patients, it must be carried out at all three points; 
previous studies have shown that drug-related 
problems are more likely to occur when reconciling 
medications at admission, discharge and transfer23,24.
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Limitations and expectations
This study had limitations related to institutional 
characteristics. The data were obtained from the 
secondary records of clinical pharmacists, which 
includes professionals in training, since our institution 
is a teaching hospital. Additionally, the demands of 
the multiprofessional team may lead pharmacists to 
focus on patient care rather than on the reporting of 
items considered essential to the bundle.
The proposed pharmaceutical care bundle is a 
comprehensive instrument which was tested locally 
at a tertiary university hospital. The results suggested 
that it may serve as a guide for pharmaceutical 
education and the training of new professionals in 
the institution, as well as contribute to the planning 
and adjustment of pharmaceutical interventions 
according to the profile and specialty of each 
department. The bundle can also be used by other 
hospitals with a similar health care profile in order to 
implement or improve a clinical pharmacy service.
We suggest that future studies pursue the 
development of specific bundles for different specialties 
or areas of care considering the characteristics and 
profile of each patient group.
This study aimed to develop and apply a 
pharmaceutical evaluation instrument to guide the 
clinical activities of pharmacists and help standardize 
their conduct and interventions. The proposed bundle 
is a comprehensive instrument which can serve as a 
guide for pharmaceutical education and the training 
of new professionals.
The bundle category with the most interventions 
was medication review, likely due to the hospital’s 
complexity, differences between patients, and 
institutional policies.
This instrument can be used as the basis for 
instruments tailored to different specialties or areas 
of health care with different levels of complexity and 
patient profiles.
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